UK markets closed
NIKKEI 225
38,835.10 +599.03 (+1.57%) HANG SENG
18,479.37 -98.93 (-0.53%) CRUDE OIL
78.45 -0.03 (-0.04%) GOLD FUTURES
2,321.80 -9.40 (-0.40%) DOW
38,893.04 +40.77 (+0.10%) Bitcoin GBP
50,461.12 +87.47 (+0.17%)
Immatics N.V. (IMTX)
NasdaqCM - NasdaqCM Real-time price. Currency in USD
Add to watchlist
As of 03:29PM EDT. Market open.
Loading interactive chart…
- Globe Newswire
Immatics Announces Full Year 2023 Financial Results and Corporate Update
Interim clinical data update on ACTengine® IMA203 GEN1 (PRAME) in melanoma at RP2D in November 2023: 50% confirmed objective response rate with median duration of response not reached at median follow-up of 14.4 months; IMA203 was well toleratedRegistration-enabling randomized Phase 2/3 trial for ACTengine® IMA203 GEN1 in 2L+ melanoma planned to begin in 2024 Next data update on IMA203 GEN1 and IMA203CD8 GEN2 planned for 2H 2024 First clinical data updates for Immatics’ next-generation TCR Bispe
- Simply Wall St.
With 52% institutional ownership, Immatics N.V. (NASDAQ:IMTX) is a favorite amongst the big guns
Key Insights Institutions' substantial holdings in Immatics implies that they have significant influence over the...
- Simply Wall St.
Immatics' (NASDAQ:IMTX) investors will be pleased with their notable 35% return over the last year
These days it's easy to simply buy an index fund, and your returns should (roughly) match the market. But if you pick...
© 2024 Yahoo. All rights reserved.